| Dr Charlene Lynn Alford-mercier, DO | |
|
14551 Hope Center Loop Ste 100, Fort Myers, FL 33912-4705 | |
| (239) 936-2316 | |
| (239) 834-6106 |
| Full Name | Dr Charlene Lynn Alford-mercier |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 31 Years |
| Location | 14551 Hope Center Loop Ste 100, Fort Myers, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083659718 | NPI | - | NPPES |
| 9541333 | Other | FL | CIGNA HEALTHCARE |
| 51213 | Other | FL | BCBS |
| 272286100 | Medicaid | FL | |
| P00097180 | Other | FL | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | OS6881 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiology Regional Center P A | 9638151756 | 53 |
News Archive
A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.
A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
› Verified 7 days ago
| Entity Name | Amin Radiology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700873981 PECOS PAC ID: 3072503788 Enrollment ID: O20040514000793 |
News Archive
A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.
A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
› Verified 7 days ago
| Entity Name | Radiology Regional Center P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407809262 PECOS PAC ID: 9638151756 Enrollment ID: O20040603000024 |
News Archive
A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.
A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
› Verified 7 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20040714001317 |
News Archive
A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.
A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
› Verified 7 days ago
| Entity Name | Elite Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346516853 PECOS PAC ID: 2466496880 Enrollment ID: O20050616000704 |
News Archive
A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.
A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
› Verified 7 days ago
| Entity Name | Partners Imaging Center Of Sarasota Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548205271 PECOS PAC ID: 0042217861 Enrollment ID: O20061108000417 |
News Archive
A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.
A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
› Verified 7 days ago
| Entity Name | Rose Radiology Centers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629162904 PECOS PAC ID: 2961451315 Enrollment ID: O20141022002331 |
News Archive
A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.
A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charlene Lynn Alford-mercier, DO 3660 Broadway, Fort Myers, FL 33901-8005 Ph: (239) 936-2316 | Dr Charlene Lynn Alford-mercier, DO 14551 Hope Center Loop Ste 100, Fort Myers, FL 33912-4705 Ph: (239) 936-2316 |
News Archive
A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.
A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
› Verified 7 days ago
Stuart A Bobman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 14551 Hope Center Loop Ste 100, Fort Myers, FL 33912 Phone: 239-936-2316 | |
Victor H Gregory, DO Radiology Medicare: Not Enrolled in Medicare Practice Location: 3680 Broadway, Fort Myers, FL 33901 Phone: 239-936-2316 | |
Dr. Mai F Saif, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 63 Barkley Cir, Ste. 100 & 101, Fort Myers, FL 33907 Phone: 239-938-3500 Fax: 239-278-0588 | |
Dr. Thomas Anderson Elkins, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 14551 Hope Center Loop Ste 100, Fort Myers, FL 33912 Phone: 239-936-4068 Fax: 239-936-6989 | |
Peter H. Blitzer, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 7341 Gladiolus Dr, Fort Myers, FL 33908 Phone: 239-489-3420 Fax: 239-489-3219 | |
Dr. Michael J Weiss, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 63 Barkley Cir, Ste. 100 & 101, Fort Myers, FL 33907 Phone: 239-938-3500 Fax: 239-278-0588 | |
William B Hearn, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 14551 Hope Center Loop Ste 100, Fort Myers, FL 33912 Phone: 239-936-2316 Fax: 239-936-3009 |